Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2. (2021)
Attributed to:
AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1093/jac/dkab135
PubMed Identifier: 34075418
Publication URI: http://europepmc.org/abstract/MED/34075418
Type: Journal Article/Review
Volume: 76
Parent Publication: The Journal of antimicrobial chemotherapy
Issue: 8
ISSN: 0305-7453